An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Recruiting in Palo Alto (17 mi)

+16 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Allakos, Inc.

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.

Eligibility Criteria

Inclusion Criteria

I have signed a consent form.

I finished or was discontinued from Study AK002-003 but am willing to start extended dosing soon.

I am willing to track changes in my diet from the start of the study.

Treatment Details

Interventions

• AK002 (Monoclonal Antibodies)

Participant Groups

Group I: 1 to 3.0 mg/kg of AK002 Experimental Treatment 1 Intervention

Subjects in this arm will receive 26 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Cincinnati Children's Hospital Cincinnati, OH

University of Utah Salt Lake City, UT

Mount Sinai New York, NY

University of Pennsylvania Philadelphia, PA

More Trial Locations

Who Is Running the Clinical Trial?

Allakos, Inc. Lead Sponsor

Allakos Inc. Lead Sponsor

References